Kensaku Kohrogi

Kensaku Kohrogi

Auto-generated profile, based on publicly available information

Kensaku Kohrogi

Department of Pediatrics Kumamoto University Hospital Kumamoto Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
KKKensaku Kohrogi
Kensaku Kohrogi
SHShinjiro Hino
Shinjiro Hino
ASAkihisa Sakamoto
Akihisa Sakamoto
KAKotaro Anan
Kotaro Anan
RTRyuta Takase
Ryuta Takase
MNMitsuyoshi Nakao
Mitsuyoshi Nakao
Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depending on cellular lineages also exist. Lysine-specific demethylase-1 (LSD1) has been reported to be crucial for human leukemogenesis, which is currently one of the emerging therapeutic targets. However, metabolic roles of LSD1 and lineage-dependent factors remain to be elucidated in AML cells. Here, we show that LSD1 directs a hematopoietic lineage-specific metabolic program in AML subtypes. Erythroid leukemia (EL) cells particularly showed activated glycolysis and high expression of LSD1 in both AML cell lines and clinical samples. Transcriptome, chromatin immunoprecipitation–sequencing, and metabolomic analyses revealed that LSD1 was essential not only for glycolysis but also for heme synthesis, the most characteristic metabolic pathway of erythroid origin. Notably, LSD1 stabilized the erythroid transcription factor GATA1, which directly enhanced the expression of glycolysis and heme synthesis genes. In contrast, LSD1 epigenetically downregulated the granulo-monocytic transcription factor C/EBPα. Thus, the use of LSD1 knockdown or chemical inhibitor dominated C/EBPα instead of GATA1 in EL cells, resulting in metabolic shifts and growth arrest. Furthermore, GATA1 suppressed the gene encoding C/EBPα that then acted as a repressor of GATA1 target genes. Collectively, we conclude that LSD1 shapes metabolic phenotypes in EL cells by balancing these lineage-specific transcription factors and that LSD1 inhibitors pharmacologically cause lineage-dependent metabolic remodeling.

25 June 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
KKKensaku Kohrogi
Kensaku Kohrogi
MMMasahiro Migita
Masahiro Migita
TATadashi Anan
Tadashi Anan
TSTakeshi Sugahara
Takeshi Sugahara
KYKazuhiko Yoshimoto
Kazuhiko Yoshimoto
KNKimitoshi Nakamura
Kimitoshi Nakamura

13 March 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RKRyunosuke Kudo
Ryunosuke Kudo
KKKensaku Kohrogi
Kensaku Kohrogi
THTakaaki Hijioka
Takaaki Hijioka
MHMasayoshi Hamaguchi
Masayoshi Hamaguchi
OMOsamu Matsuo
Osamu Matsuo
KNKimitoshi Nakamura
Kimitoshi Nakamura